- Home
- CNTB vs MIST Comparison
CNTB vs MIST Comparison
Compare CNTB & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- MIST
- Stock Information
- Founded
- CNTB 2012
- MIST 2003
- Country
- CNTB United States
- MIST Canada
- Employees
- CNTB N/A
- MIST N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- MIST Health Care
- Exchange
- CNTB Nasdaq
- MIST Nasdaq
- Market Cap
- CNTB 114.8M
- MIST 145.3M
- IPO Year
- CNTB 2021
- MIST N/A
- Fundamental
- Price
- CNTB $1.60
- MIST $1.97
- Analyst Decision
- CNTB Strong Buy
- MIST Strong Buy
- Analyst Count
- CNTB 2
- MIST 3
- Target Price
- CNTB $7.50
- MIST $6.33
- AVG Volume (30 Days)
- CNTB 174.9K
- MIST 1.2M
- Earning Date
- CNTB 09-05-2025
- MIST 11-11-2025
- Dividend Yield
- CNTB N/A
- MIST N/A
- EPS Growth
- CNTB N/A
- MIST N/A
- EPS
- CNTB N/A
- MIST N/A
- Revenue
- CNTB $1,965,000.00
- MIST N/A
- Revenue This Year
- CNTB N/A
- MIST N/A
- Revenue Next Year
- CNTB N/A
- MIST N/A
- P/E Ratio
- CNTB N/A
- MIST N/A
- Revenue Growth
- CNTB N/A
- MIST N/A
- 52 Week Low
- CNTB $1.55
- MIST $0.63
- 52 Week High
- CNTB $2.20
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- CNTB 41.47
- MIST 67.34
- Support Level
- CNTB $1.63
- MIST $1.75
- Resistance Level
- CNTB $1.79
- MIST $1.83
- Average True Range (ATR)
- CNTB 0.19
- MIST 0.09
- MACD
- CNTB -0.04
- MIST 0.02
- Stochastic Oscillator
- CNTB 7.69
- MIST 79.49
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).